一种多功能纳米载体用于高效TRAIL基因治疗小鼠促结缔组织增生性肝细胞癌
研究开发肿瘤靶向LCPP纳米颗粒递送TRAIL质粒DNA至小鼠肝细胞癌,CaP核pH响应释放Ca2+上调DR5克服TRAIL耐药,TRAIL表达还通过逆转活化肝星状细胞或诱导其凋亡减轻纤维化;联合索拉非尼可抑制肝癌进展及肝纤维化。
要点
- LCPP纳米颗粒将TRAIL pDNA递送至肝细胞癌,Ca2+内流上调DR5克服TRAIL耐药。
- TRAIL表达通过逆转活化肝星状细胞或诱导其凋亡减轻肝癌周围肝纤维化。
- LCPP纳米颗粒递送的TRAIL pDNA联合索拉非尼可抑制肝癌进展及肝纤维化。
核心结论
- HCC靶向LCPP纳米颗粒递送的TRAIL pDNA联合常规索拉非尼治疗可减轻HCC进展及肝纤维化。
- 研究提出一种基于TRAIL的癌症治疗策略,可能可开发用于临床应用。
研究设计与样本
- 研究开发肿瘤靶向LCPP(脂质/钙/磷酸盐/鱼精蛋白)纳米颗粒,在小鼠HCC模型中递送TRAIL质粒DNA至HCC细胞。
主要发现
- TRAIL pDNA封装于pH刺激响应性磷酸钙核中,加入鱼精蛋白以促进pDNA的核递送。
- CaP核释放的Ca2+通过钙内流依赖性DR5上调克服TRAIL耐药。
- TRAIL表达通过逆转活化HSC至静息状态或直接诱导活化HSC凋亡,减轻HCC周围肝组织纤维化。
- LCPP纳米颗粒递送的TRAIL pDNA联合索拉非尼可减轻HCC进展及肝纤维化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The anticancer efficacy of TNF-related apoptosis-inducing ligand (TRAIL)-based therapy is limited because of systemic toxicity, poor bioavailability, and development of TRAIL resistance. We developed a tumor-targeted LCPP (lipid/calcium/phosphate/protamine) nanoparticle (NP) to deliver TRAIL plasmid DNA (pDNA) into hepatocellular carcinoma (HCC) cells in a mouse model of HCC. TRAIL pDNA was encapsulated in a pH stimuli-responsive calcium phosphate (CaP) core, and protamine was added to facilitate nuclear delivery of pDNA. In addition, intracellular release of Ca2+ from the CaP core overcame TRAIL resistance by calcium influx-dependent DR5 up-regulation. TRAIL expression also attenuated fibrosis in liver tissues surrounding HCCs by reverting activated hepatic stellate cells (HSCs) to a quiescent state or by directly inducing apoptosis in activated HSCs. CONCLUSION: TRAIL pDNA delivered by HCC-targeted LCPP NPs in combination with conventional sorafenib treatment attenuated HCC progression as well as liver fibrosis. Overall, our study presents an effective TRAIL-based cancer therapy that could be developed for clinical applications. (Hepatology 2018;67:899-913).
引用
- Liu CH, Chern GJ, Hsu FF, et al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology. 2018. PMID: 28885731. doi:10.1002/hep.29513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。